Penumbra, Inc. Aktie News

ALAMEDA, Calif., 30. Juli 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), das weltweit führende Thrombektomie-Unternehmen, berichtete heute über die Finanzergebnisse für das am 30. Juni 2026 endende zweite Quartal.

Erstes und bisher einziges CAVT-Gerät für Schlaganfälle zeigte hohe Rekanalisationsraten, kurze Prozedurzeiten und niedrige Komplikationsraten ALAMEDA, Calif., 22. Juli 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), das weltweit führende Thrombektomie-Unternehmen, gab die Ergebnisse von THUNDER bekannt, einer Investigational Device Exemption (IDE)-Studie, zur Bewertung der Sicherheit und Wirk...

ALAMEDA, Calif., 7. Juli 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), das weltweit führende Thrombektomie-Unternehmen, gab den Start seiner FORWARD-Studie bekannt, einer internationalen, realen prospektiven multizentrischen Studie.

The THUNDERBOLT TM Computer Assisted Vacuum Thrombectomy (CAVT TM ) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal ALAMEDA, Calif., June 15, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has secured CE Mark in Europe for THUNDERBOLT™, further laying the ...

THUNDERBOLT is the first CAVT platform to deliver modulated aspiration for acute ischemic stroke — enabling faster, more complete clot removal ALAMEDA, Calif., June 11, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced it has received U.S. Food and Drug Administration (FDA) clearance for THUNDERBOLT™, expanding its computer assisted vacuum thro...

ALAMEDA, Calif., May 6, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

ALAMEDA, Calif., April 13, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) announced 90-day results of the landmark STORM-PE randomized controlled trial (RCT), which found that patients with acute intermediate-high risk pulmonary embolism (PE) who were treated with computer assisted vacuum thrombectomy (CAVT™) plus anticoagulation achieved greater functional improvement, including walking signi...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Penumbra, Inc. (NYSE: PEN) to Boston Scientific Corporation (NYSE: BSX). Under the terms of the proposed transaction, shareholders of Penumbra will receive $374.00 in cash or 3.8721 shares of Boston Sci...